口服生长素释放肽受体激动剂AC01治疗HFrEF的1b/2a期研究
本研究评估新型口服钙增敏正性肌力药及生长素释放肽受体激动剂AC01在射血分数降低心力衰竭患者中的安全性与耐受性。研究为随机、双盲、安慰剂对照的1b/2a期试验,共纳入58例患者。结果显示AC01在28天内安全且耐受性良好,未发现重大安全性问题。
要点
- AC01在HFrEF患者中28天治疗安全且耐受性良好,无治疗相关严重不良事件。
- 最常见治疗中出现的不良事件为低血压、非持续性室性心动过速、呼吸困难。
- 心电图未见心动过速、新发快速心律失常、心肌缺血或传导异常征象。
核心结论
- 在HFrEF患者中,AC01治疗28天表现出安全性和良好的耐受性,未发现重大安全性问题。
- 研究结果支持在更大规模研究中进一步评估AC01。
研究设计与样本
- 这是一项随机、双盲、安慰剂对照的1b/2a期研究,在荷兰、英国、瑞典和意大利的14个研究中心开展。
- 所有患者均植入经静脉植入型心律转复除颤器用于一级预防,并具有备用起搏功能以防止严重心动过缓。
主要发现
- 1b期有12例AC01相关不良事件,2a期有18例AC01相关不良事件。
- 41例接受AC01的患者中有33例(80%)报告轻度或中度治疗中出现的不良事件,17例接受安慰剂的患者中有12例(71%)报告。
- 治疗中出现的不良事件最常见为低血压、非持续性室性心动过速、呼吸困难、高血糖、头晕或眩晕及头痛。
- 心电图数据显示无明显心动过速、新发快速心律失常、心肌缺血或形态学或传导异常征象。
- 未报告症状性低血压病例,AC01对高敏心肌肌钙蛋白I和NT-proBNP无明显影响。
关键数值与推荐
- 主要结局为安全性和耐受性,通过体格检查、生命体征、实验室检查及12导联心电图进行监测。
- 1b期在第12天结束研究,2a期在第42天结束研究。
- 心脏节律通过贴片设备远程连续监测,1b期监测至第9天,2a期监测至第4天。
- 入选标准包括静息心率均值55-90次/分,窦性心律或持续性、永久性、阵发性房颤或房扑(仅2a期允许)。
临床怎么用
- AC01在早期研究中未显示对高敏心肌肌钙蛋白I或NT-proBNP产生明显影响。
- 该药在合并植入型心律转复除颤器且具有备用起搏的HFrEF患者中耐受性良好。
- 后续需在更大规模研究中进一步验证AC01的有效性和长期安全性。
局限性
- 本研究为早期探索性研究,样本量有限,共58例患者。
- 治疗期较短,最长仅28天,缺乏长期安全性数据。
- 2a期纳入的房颤或房扑患者比例未在摘要中详细描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The central problem in heart failure with reduced ejection fraction (HFrEF) is reduced contractility. Existing inotropes are associated with adverse effects. In this exploratory study, we aimed to assess the safety and tolerability of AC01, a novel oral calcium-sensitising inotrope and ghrelin receptor agonist, in patients with HFrEF. METHODS: In this phase 1b/2a, randomised, double-blind, placebo-controlled study, adults aged 18-80 years with heart failure for at least 6 months and an ejection fraction of 40% or lower were enrolled at 14 sites in the Netherlands, the UK, Sweden, and Italy. All patients had a transvenous implantable cardioverter defibrillator for primary prevention, with back-up pacing to protect against excessive bradycardia. Other eligibility criteria included sinus rhythm or permanent, persistent, or paroxysmal atrial fibrillation or flutter (only allowed in phase 2a), with a mean resting heart rate of 55-90 beats per min. Randomisation used permuted blocks, with block sizes of four for phase 1b and three for phase 2a. In phase 1b, patients were enrolled in four sequential dose cohorts and randomly assigned 3:1 to ascending doses of AC01 (0·1 mg, 0·3 mg, 1·0 mg, or 3·0 mg) or placebo twice daily for 7 days. In phase 2a, patients were randomly assigned 1:1:1 to parallel groups receiving 1·0 mg AC01, 3·0 mg AC01 (1·0 mg AC01 on days 1 and 2 and 3·0 mg thereafter), or placebo orally twice daily for 28 days. Patients, study personnel, outcomes assessors, those analysing the data, and the sponsor were masked to treatment assignment. The primary outcome was safety and tolerability. Safety was monitored by physical examination, vital signs, safety laboratory assessments, and 12-lead electrocardiograms (ECGs) periodically during the treatment period and until the end-of-study visit (day 12 in phase 1b and day 42 in phase 2a), and cardiac rhythm was continuously monitored remotely using a patch device until day 9 in phase 1b and until day 4 in phase 2a. Adverse or unexpected events, signs, or symptoms were recorded. This study is registered with ClinicalTrials.gov, NCT05642507, and has been completed. FINDINGS: Between Feb 23, 2023, and Aug 28, 2025, 58 patients (53 [91%] male and five [9%] female patients with a median age of 66·0 years [IQR 60·3-72·0]) were randomly assigned: 32 in phase 1b and 26 in phase 2a. In phase 1b, four cohorts of eight patients were enrolled; in each cohort, six patients were allocated to AC01 and two to placebo, with AC01 dose cohorts of 0·1 mg, 0·3 mg, 1·0 mg, and 3·0 mg. In phase 2a, nine patients were allocated to 1·0 mg AC01, eight to 3·0 mg AC01, and nine to placebo. There were 12 AC01-related adverse events in phase 1b and 18 in phase 2a. There were no AC01-related serious adverse events; one treatment-related serious adverse event of increased high-sensitivity cardiac troponin I concentration occurred in a patient receiving placebo in phase 1b. Mild or moderate treatment-emergent adverse events were reported in 33 (80%) of 41 patients receiving AC01 and 12 (71%) of 17 patients receiving placebo. The most common treatment-emergent adverse events were hypotension, non-sustained ventricular tachycardia, dyspnoea, hyperglycaemia, dizziness or vertigo, and headache. ECG data showed no apparent signs of tachycardia, new-onset tachyarrhythmias, myocardial ischaemia, or morphological or conduction abnormalities. No case of symptomatic hypotension was reported, and there were no apparent effects of AC01 on high-sensitivity cardiac troponin I or NT-proBNP. There were no deaths during the study. INTERPRETATION: In patients with HFrEF, AC01 over 28 days appeared safe and well tolerated, and no major harms were identified in this early-phase study. These findings support further investigations of AC01 in larger studies. FUNDING: AnaCardio.
引用
- Lund, Barandiarán Aizpurua, Bollano, et al. Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study. Lancet. 2026. PMID: 42341796. doi:10.1016/S0140-6736(26)00904-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。